# Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

> **NCT05642949** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Minghui Pharmaceutical Pty Ltd** · enrollment: 400 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** MHB036C

## Key facts

- **NCT ID:** NCT05642949
- **Lead sponsor:** Minghui Pharmaceutical Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-01-23
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642949, "Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05642949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*